QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marchesini, G. Articles by Bianchi, G. Search for Related Content PubMed PubMed Citation Articles by Marchesini, G. Articles by Bianchi, G.

---

4th Amino Acid Assessment Workshop

Branched-Chain Amino Acid Supplementation in Patients with Liver Diseases¹

Department of Internal Medicine, "Alma Mater Studiorum," University of Bologna, Italy

²To whom correspondence should be addressed. E-mail: giulio.marchesini{at}unibo.it.

Because of their peculiar role in whole-body nitrogen metabolism and the competitive action on amino acid transport across the blood–brain barrier, branched-chain amino acids (BCAAs) have been extensively used in subjects with liver disease to preserve or to restore muscle mass and to improve hepatic encephalopathy. There are no data regarding safe limits of BCAA administration; the results appear to be better when BCAA-enriched formulas or BCAA-supplemented diets are preferred to pure BCAA formulas. Improved nitrogen retention might ameliorate the nutritional status, a prognostic index of long-term survival in cirrhosis and of short-term survival in patients undergoing surgical procedures. The effects on nutrition and ultimately on prognosis of patients with advanced cirrhosis were confirmed in a large multicenter, long-term trial where oral BCAA supplements were compared with equicaloric or equinitrogenous–equicaloric supplements (maltodextrin or lactoalbumin). Similarly, BCAA treatment improved the prognosis of patients with hepatocellular carcinoma, treated by surgical resection or chemoembolization, and of liver transplant patients. The mechanism(s) for the beneficial effects of BCAAs might be mediated by their stimulating activity on hepatocyte growth factor, favoring liver regeneration. The debate regarding the potential effectiveness of BCAAs dates back to the early 1980s. The number of patients who cannot tolerate dietary proteins in amounts sufficient to meet the higher catabolism of advanced liver disease is probably low, but BCAAs remain the sole treatment of proved efficacy in this specific setting.

KEY WORDS: • nutrition • cirrhosis • nitrogen balance • encephalopathy • survival • hepatocyte growth factor

This article has been cited by other articles:

				M. P. Engelen, E. P. Rutten, C. L. De Castro, E. F. Wouters, A. M. Schols, and N. E. Deutz Supplementation of soy protein with branched-chain amino acids alters protein metabolism in healthy elderly and even more in patients with chronic obstructive pulmonary disease Am. J. Clinical Nutrition, February 1, 2007; 85(2): 431 - 439. [Abstract] [Full Text] [PDF]

				D. R. Mager, L. J. Wykes, E. A. Roberts, R. O. Ball, and P. B. Pencharz Branched-Chain Amino Acid Needs in Children with Mild-to-Moderate Chronic Cholestatic Liver Disease J. Nutr., January 1, 2006; 136(1): 133 - 139. [Abstract] [Full Text] [PDF]